Avanir Pharma (AVNR) files a $150M mixed shelf. The drug developer only says it will use any...


Avanir Pharma (AVNR) files a $150M mixed shelf. The drug developer only says it will use any proceeds for general corporate purposes, which could include financing clinical trials and/or commercializing Nuedexta. Avanir had $65.8M in cash on its balance sheet as of March 30, and $29.1M in debt.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs